FDAã¯é£éçãŸãã¯GEJçã«å¯ŸããŠãã³ãããªãºãããæ¿èªããŸãã (è±èªãµã€ãïŒ
âæ¬ãµã€ãã®Google翻蚳
FDAã¯é£éçãŸãã¯GEJçã«å¯ŸããŠãã³ãããªãºãããèªããŸãã
2021幎3æ22æ¥ãé£åå»è¬åå±ã¯ã転移æ§ãŸãã¯å±æé²è¡æ§é£éãŸãã¯èé£éïŒGEJïŒïŒãšãã»ã³ã¿ãŒ1ã®è «çïŒã®æ£è ã«å¯ŸããŠããã©ããããã³ãã«ãªãããªããžã³ããŒã¹ã®ååŠçæ³ãšçµã¿åããããã³ãããªãºããïŒKeytrudaãMerck SharpïŒDohme Corp.ïŒãæ¿èªããŸãããå€ç§çåé€ãŸãã¯æ ¹æ²»çååŠæŸå°ç·çæ³ã®åè£ã§ã¯ãªãçè «ïŒèé£éæ¥åéšãã5ã»ã³ãã¡ãŒãã«äžïŒã
æå¹æ§ã¯KEYNOTE-590ïŒNCT03189719ïŒã§è©äŸ¡ãããŸãããããã¯ãå€ç§çåé€ãŸãã¯æ ¹æ²»çååŠæŸå°ç·çæ³ã®åè£ã§ã¯ãªãã£ã転移æ§ãŸãã¯å±æé²è¡é£éãŸãã¯èé£éæ¥åéšçã®749人ã®æ£è ãç»é²ããå€æœèšã©ã³ãã åãã©ã»ãå¯Ÿç §è©Šéšã§ããPD-L1ã®ç¶æ ã¯ãPD-L1 IHC 22C3pharmDxãããã䜿çšããŠãã¹ãŠã®æ£è ã®è «çæšæ¬ã§äžå çã«æ±ºå®ãããŸãããæ£è ã¯ã蚱容ã§ããªãæ¯æ§ãŸãã¯çŸæ£ã®é²è¡ãŸã§ãã·ã¹ãã©ãã³ããã³ãã«ãªããŠã©ã·ã«ãšçµã¿åããããã³ãããªãºãããŸãã¯ã·ã¹ãã©ãã³ããã³ãã«ãªããŠã©ã·ã«ãšçµã¿åããããã©ã»ãã«ã©ã³ãã åïŒ1ïŒ1ïŒãããŸããã
RECIST 1.1ã«åŸã£ãŠæ²»éšè²¬ä»»å»åž«ãè©äŸ¡ããäž»ãªæå¹æ§ã¢ãŠãã«ã ææšã¯å šçåæéïŒOSïŒãšç¡å¢æªçåæéïŒPFSïŒã§ããïŒèåšãããæ倧10ã®æšçç å€ãšæ倧5ã€ã®æšçç å€ã远跡ããããã«ä¿®æ£ïŒããã®è©Šéšã§ã¯ãååŠçæ³ã§ãã³ãããªãºããã«ã©ã³ãã åãããæ£è ã®OSãšPFSã«çµ±èšçã«ææãªæ¹åãèŠãããŸãããOSäžå€®å€ã¯ãã ãããªãºãã矀ã§12.4ãæïŒ95ïŒ CIïŒ10.5ã14.0ïŒã§ãã£ãã®ã«å¯ŸããååŠçæ³çŸ€ã§ã¯9.8ãæïŒ95ïŒ CIïŒ8.8ã10.8ïŒã§ããïŒHR 0.73; 95ïŒ CIïŒ0.62ã0.86; p <0.0001ïŒ ãPFSã®äžå€®å€ã¯ãããã6.3ïŒ95ïŒ CIïŒ6.2ã6.9ïŒããã³5.8ãæïŒ95ïŒ CIïŒ5.0ã6.0ïŒã§ããïŒHR 0.65; 95ïŒ CIïŒ0.55ã0.76; p <0.0001ïŒã
KEYNOTE-590ã§ãã ãããªãºããã®äœµçšçæ³ãåããæ£è ã®20ïŒ ä»¥äžã§å ±åãããæãäžè¬çãªå¯äœçšã¯ãæªå¿ã䟿ç§ãäžç¢ãååãå£å çãåŠæ æ/ç¡åçãé£æ¬²æžéãããã³äœéæžå°ã§ããã
é£éããã«æšå¥šããããã³ãããªãºããã®çšéã¯ã3é±éããšã«200 mgããŸãã¯6é±éããšã«400mgã§ãã
ãã®ã¬ãã¥ãŒã¯ãFDAè «çåŠã»ã³ã¿ãŒãªããšã¯ã»ã¬ã³ã¹ã®ã€ãã·ã¢ããã§ããProjectOrbisã®äžã§å®æœãã ãŸãããProject Orbisã¯ãåœéçãªããŒãããŒéã§è «çè¬ã®åææåºãšã¬ãã¥ãŒãè¡ãããã®ãã¬ãŒã ã¯ãŒã¯ãæäŸããŸãããã®ã¬ãã¥ãŒã§ã¯ãFDAã¯ãªãŒã¹ãã©ãªã¢æ²»ç補åå±ïŒTGAïŒãã«ããä¿å¥çãã¹ã€ã¹ã®ã¹ã€ã¹ã¡ãã£ãã¯ãšååããŸãããã¢ããªã±ãŒã·ã§ã³ã®ã¬ãã¥ãŒã¯ãä»ã®èŠå¶åœå±ã§é²è¡äžã§ãã
ãã®ã¬ãã¥ãŒã¯äœ¿çš ãªã¢ã«ã¿ã€ã ãªã³ã³ããžãŒã¬ãã¥ãŒ åã«å šäœã®èšåºå¿çšãããã³ã®ãã¡ã€ãªã³ã°ã«ããŒã¿æåºãåçåïŒRTORïŒãã€ãããããã°ã©ã ãã¢ã»ã¹ã¡ã³ãæŽå©ãFDAã®è©äŸ¡ã容æã«ããããã«ãç³è«è ããã®èªçºçãªæåŸããFDAã¯ãFDAã®ç®æšæ¥ã®çŽ3é±éåã«ãã®ç³è«ãæ¿èªããŸããã
ãã®ç³è«ã«ã¯åªå 審æ»ãäžããããŸãããFDAã®è¿ éããã°ã©ã ã®èª¬æã¯ãã æ¥çåãã¬ã€ãã³ã¹ïŒæ·±å»ãªç¶æ ã®ããã®è¿ éããã°ã©ã -å»è¬åããã³çç©è£œå€ãã«ãããŸãã
å»çå°é家ã¯ãå»è¬åããã³ããã€ã¹ã®äœ¿çšã«é¢é£ãããšæããããã¹ãŠã®é節ãªæ害äºè±¡ãFDAã® MedWatchã¬ããŒãã·ã¹ãã ã«å ±åãããã1-800-FDA-1088ã«é»è©±ããå¿ èŠããããŸãã
æ²»éšãªã³ã³ããžãŒè£œåçšã®åäžã®æ£è ã®INDSã®æ¯æŽã®ããã«ãå»çå°é家ã¯ãOCEã®é£çµ¡ãããããããžã§ã¯ããåæ»240-402-0004ã§ããŸãã¯é»åã¡ãŒã«OncProjectFacilitate@fda.hhs.govãã
COVID-19ãã³ãããã¯ã®è©³çŽ°ã«ã€ããŠã¯ã次ã®ãªãœãŒã¹ãåç §ããŠãã ããã
FDAïŒã³ãããŠã€ã«ã¹ç 2019ïŒCOVID-19ïŒ
NCIïŒã³ãããŠã€ã«ã¹ïŒããæ£è ãç¥ã£ãŠããã¹ãããš
CDCïŒã³ãããŠã€ã«ã¹ïŒCOVID-19ïŒ